Published in Semin Oncol on August 01, 1999
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol (2006) 1.30
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol (2013) 1.07
Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem (2009) 1.06
Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One (2012) 0.99
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog (2011) 0.96
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res (2007) 0.86
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol (2013) 0.82
Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. Breast Cancer (Auckl) (2011) 0.81
Therapeutic monoclonal antibodies in oncology. J R Soc Med (2005) 0.79
Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br J Cancer (2010) 0.79
New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.78
Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int (2014) 0.78
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) (2010) 0.76
Profiling serum HER-2/NEU in prostate cancer. Hippokratia (2013) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Expression of cellular oncogenes in human malignancies. Science (1984) 4.48
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol (1997) 3.66
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol (2000) 3.56
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 3.33
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res (1994) 3.03
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
Prognostic classification of breast ductal carcinoma-in-situ. Lancet (1995) 2.70
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
The x gene is essential for HTLV replication. Science (1985) 2.44
Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science (1988) 2.31
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene (1998) 1.98
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene (1997) 1.78
Regulation of expression of human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A (1986) 1.76
HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat (1998) 1.69
Expression of cellular oncogenes during embryonic and fetal development of the mouse. Proc Natl Acad Sci U S A (1984) 1.68
Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science (1985) 1.65
First-line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 1.60
Identification and characterization of the protein encoded by the human N-myc oncogene. Science (1986) 1.58
Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem (1996) 1.53
Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens. Proc Natl Acad Sci U S A (1985) 1.51
HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells (1997) 1.49
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res (2000) 1.43
HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science (1988) 1.41
Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res (1994) 1.41
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer (2009) 1.41
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene (1999) 1.39
FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene (2012) 1.39
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene (1993) 1.38
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene (1997) 1.35
Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene (1995) 1.34
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res (1999) 1.33
Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin Cancer Res (2001) 1.31
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene (1996) 1.31
Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res (1991) 1.28
Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol (2001) 1.28
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol (2005) 1.25
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res (1990) 1.23
Proto-oncogenes and human cancers. N Engl J Med (1987) 1.17
Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res (1999) 1.16
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer (1991) 1.14
Expression of p21 ras oncoproteins in human cancers. Cancer Res (1986) 1.13
A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV-I and HIV-1: a clinical and molecular analysis. Am J Hematol (1989) 1.11
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene (1992) 1.09
Studies of the retinoblastoma gene in human sarcomas. Oncogene (1989) 1.08
Detection of antibodies to human T-lymphotropic virus type 1 (HTLV-1). Transfusion (1988) 1.06
Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals. Blood (1989) 1.05
Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol (2000) 1.01
Herceptin. Handb Exp Pharmacol (2008) 1.01
Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol (2000) 1.01
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer (2001) 0.99
Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene (1993) 0.99
Identification of new gene products coded from X regions of human T-cell leukemia viruses. Proc Natl Acad Sci U S A (1985) 0.99
Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol (1994) 0.96
Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res (1988) 0.96
HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res (1990) 0.94
Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins. Mol Cell Biol (1986) 0.94
Expression of protooncogene c-myb in normal human hematopoietic cells. Blood (1989) 0.93
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol (1993) 0.92
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors? Science (1988) 0.92
The transmembrane heregulin precursor is functionally active. J Biol Chem (2001) 0.91
HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med (1990) 0.91
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg (2001) 0.88
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol (1999) 0.87
Organ specific expression of ras oncoproteins during growth and development of the rat. Mol Cell Biochem (1986) 0.86
Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res (1988) 0.85
HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science (1987) 0.85
Mutations of the p53 gene are not detectable in human testicular tumors. Mod Pathol (1994) 0.83
Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol (1994) 0.83
A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci U S A (1999) 0.82
Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res (1988) 0.82
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res (2000) 0.82
Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res (1992) 0.82
A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Cancer (1991) 0.82
A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol (1998) 0.81
Expression of the nm23 gene and breast cancer prognosis. J Natl Cancer Inst (1991) 0.80
Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer. Chest (1994) 0.80
Human c-FES is a nuclear tyrosine kinase. Oncogene (1995) 0.79
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry (1998) 0.78
Cell type-specific expressions of c-ras gene products in the normal rat. Mol Cell Biochem (1987) 0.78
p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol (1994) 0.78
186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm (1996) 0.77
Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res (1992) 0.77
Oncogenes: implications for the diagnosis and treatment of cancer. Ann Intern Med (1984) 0.76
Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. J Hematother (1998) 0.76